Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparative in vitro susceptibility of a novel fluoroquinolone antibiotic candidate WFQ-228, levofloxacin, and moxifloxacin against Mycobacterium tuberculosis.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 1 May 2021

Qiao Min, Ren Weicong, Guo Haiping, Huo Fengmin, Shang Yuanyuan, Wang Yufeng, Gao Mengqiu, Pang Yu

Abstract excerpt

OBJECTIVE: WFQ-228 is a novel developed fluoroquinolone (FQ) displaying potent antimicrobial activity against various clinical isolates of pathogens, including FQ-resistant isolates. The aim was to comparatively analyze in vitro susceptibilities of WFQ-228, levofloxacin (LFX), and moxifloxacin (MFX) against Mycobacterium tuberculosis (MTB) isolates, especially with gyrA mutations. METHODS: We selected a panel of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to DNA Gyrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Bacterial

Share to Fluoroquinolones

Share to Levofloxacin

Share to Microbial Sensitivity Tests

Share to Moxifloxacin

Share to Mycobacterium tuberculosis

Source

Identifiers

PMID: 33864922
DOI: 10.1016/j.ijid.2021.04.036

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparative in vitro susceptibility of a novel fluoroquinolone antibiotic candidate WFQ-228, levofloxacin, and moxifloxacin against Mycobacterium tuberculosis.PMID 33864922Read ↗

WQ-3810: A new fluoroquinolone with a high potential against fluoroquinolone-resistant Mycobacterium tuberculosis.Semantic proximity Read ↗

Phenotypic and genotypic characterization of levofloxacin- and moxifloxacin-resistant Mycobacterium tuberculosis clinical isolates in southern ChinaSemantic proximity Read ↗

Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.Semantic proximity Read ↗

Specific <i>gyrA</i> gene mutations correlate with high prevalence of discordant levofloxacin resistance in <i>Mycobacterium tuberculosis</i> isolates from Beijing, ChinaSemantic proximity Read ↗

Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China.Semantic proximity Read ↗

Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients.Semantic proximity Read ↗

Increased prevalence of levofloxacin-resistant Mycobacterium tuberculosis in China is associated with specific mutations within the gyrA gene.Semantic proximity Read ↗

Molecular Characterization of Levofloxacin, Moxifloxacin, Bedaquiline, Linezolid, Clofazimine, and Delamanid against Multidrug-resistant Tuberculosis in Southwest of ChinaSemantic proximity Read ↗

Re-evaluation of critical concentrations of antituberculosis fluoroquinolones in the Mycobacteria Growth Indicator Tube 960 system.Semantic proximity Read ↗

Specific gyrA Gene Mutations Correlate with High Prevalence of Discordant Levofloxacin Resistance in Mycobacterium tuberculosis Isolates from Beijing, China.Semantic proximity Read ↗

Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran.Semantic proximity Read ↗

In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.